Table of Contents As filed with the Securities and Exchange Commission on February 21, 2024 Registration No. 333-275989 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aclarion, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8071 47-3324725 (I.R.S. Employer Iden ...

Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Aclarion, Inc. Page Financial Statements Report of Independent Registered Public Accounting Firm - Haynie & Company LLP (ID# 457) F-2 Report of Independent Registered Public Accounting Firm CohnReznick LLP (ID# 596) F-3 Balance Sheets at December 31, 2023 and 2022 F-4 Statements of Operations, for the Years Ended December 31, 2023 and 2022 F-5 Statements of Changes in Stockholders’ Equity (deficit), for the Years Ended December 31, 2023 and 2022 F-6 Statements of C ...

Table of Contents As filed with the Securities and Exchange Commission on February 6, 2024 Registration No. 333-275989 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aclarion, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 (833) 275-2266 (Address, including zip code, and ...

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning 5 additional Key Opinion Leader (KOL) surgeons expected to adopt Nociscan through the Alphatec strategic partnership in 1H24 BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is l ...

Table of Contents (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on January 31, 2024 Registration No. 333-276648 (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) FORM S-1/A Pre-Effective Amendment No. 1 Delaware 8071 47-3324725 (I.R.S. Employer Identification Number) REGISTRATION STATEMENT UNDER THE SECURIT ...

Stock Issuance and Dilution - Aclarion issued 500,000 shares of ACON stock in exchange for $1,185,226 of principal and accrued interest on unsecured non-convertible notes, increasing the total number of outstanding shares to 1,791,375 [1] - The company may enact similar exchanges in the future to cover financing from those notes [1] - Increasing the total number of shares often results in a stock's price falling due to dilution of current investors' stakes [1] ACON Stock Performance - ACON stock is down 15.5% as of Monday morning, with about 367,000 shares traded compared to the daily average trading volume of 1.2 million shares [2] - The stock was down 14.4% year-to-date as of Friday's close [2] Market Context - The article mentions other stocks such as SoFi Technologies (NASDAQ:SOFI), Panbela Therapeutics (NASDAQ:PBLA), and Revelation Biosciences (NASDAQ:REVB) as part of the broader stock market news [2] - InvestorPlace typically avoids publishing commentary on companies with a market cap of less than $100 million or trading less than 100,000 shares daily due to the risks associated with low-volume stocks [3]

Table of Contents As filed with the Securities and Exchange Commission on January 22, 2024 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aclarion, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8071 47-3324725 (I.R.S. Employer Identification Number) 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 (833) 275-2266 Registration No. 333- UNITED STATES SEC ...

Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes Aclarion's 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligenc ...

Partnership aims to include Aclarion's surgical decision support technology within ATEC's AlphaInformatiX platform to better inform spine surgery Aclarion's Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveragi ...

Core Viewpoint - Aclarion, Inc. will execute a 1-for-16 reverse stock split of its common stock effective January 4, 2024, to meet Nasdaq listing standards and increase its stock price above $1.00 [1][2][4] Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on March 24, 2023, and the Board of Directors set the ratio at 1-for-16 [2] - Post-split, the number of outstanding shares will decrease from approximately 13.4 million to about 840,000 [4] - The reverse stock split will not affect the authorized number of shares, and fractional shares will be rounded up to the nearest whole share [3][4] Group 2: Impact on Securities - The reverse stock split will also apply to outstanding warrants, stock options, and restricted stock units, with adjustments made to the number of shares and exercise prices [3] - A new CUSIP number (655187201) will be assigned to the shares, which will begin trading on a split-adjusted basis on January 4, 2024 [3] Group 3: Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms through its Nociscan platform [5] - Nociscan is designed to help physicians differentiate between painful and non-painful discs in the lumbar spine, providing critical insights for treatment optimization [5]